1.
Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie A-L, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J, Marque-Juillet S, Raggueneau V, Osman J, Spentchian M, Rigaudeau S, Rousselot P, Besson C. A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. haematol [Internet]. 2022Jun.1 [cited 2024Jun.13];107(6):1454-9. Available from: https://haematologica.org/article/view/haematol.2021.280026